Trial Profile
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Adverse reactions
- Acronyms X-PAND
- Sponsors Genentech
- 07 Mar 2014 Status changed to completed as reported by ClinicalTrials.gov.
- 21 Apr 2009 Actual initiation date (Mar 2009) added as reported by ClinicalTrials.gov.
- 21 Apr 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.